Optimizing an effective combination of the new microtubule-targeting agent lisavanbulin with standard-of-care therapy for glioblastoma in patient-derived xenograft preclinical models.

ABSTRACT:

SUBMITTER: Charest A 

PROVIDER: S-EPMC8917392 | biostudies-literature | 2022 Mar

REPOSITORIES: biostudies-literature